Barriers and shortcomings in access to cardiovascular management and prevention for familial hypercholesterolemia during the COVID‐19 pandemic
Clinical Cardiology · 2023
DOI: 10.1002/clc.24059 ↗At a glance
Übersichtsarbeit in Clinical Cardiology, 2023. Written by Helen Huang and 12 co-authors. Institution: Royal College of Surgeons in Ireland, Faculty of Medicine and Health Science, Dublin, Ireland. Major MEDLINE topics: COVID-19, Hyperlipoproteinemia Type II, Atherosclerosis, Cardiovascular Diseases. Cited 2 times so far (Crossref); 140 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Familial hypercholesterolemia (FH) is a hereditary condition caused by mutations in the lipid pathway. The goal in managing FH is to reduce circulating low‐density lipoprotein cholesterol and, therefore, reduce the risk of developing atherosclerotic cardiovascular disease (ASCVD). Because FH patients were considered high risk groups due to an increased susceptible for contracting COVID‐19 infection, we hypothesized whether the effects of the pandemic hindered access to cardiovascular care. In this review, we conducted a literature search in databases Pubmed/Medline and ScienceDirect. We included a comprehensive analysis of findings from articles in English related and summarized the effects of the pandemic on cardiovascular care through direct and indirect effects. During the COVID‐19 pandemic, FH patients presented with worse outcomes and prognosis, especially those that have suffered from early ASCVD. This caused avoidance in seeking care due to fear of transmission. The pandemic severely impacted consultations with lipidologists and cardiologists, causing a decline in lipid profile evaluations. Low socioeconomic communities and ethnic minorities were hit the hardest with job displacements and lacked healthcare coverage respectively, leading to treatment nonadherence. Lock‐down restrictions promoted sedentary lifestyles and intake of fatty meals, but it is unclear whether these factors attenuated cardiovascular risk in FH. To prevent early atherogenesis in FH patients, universal screening programs, telemedicine, and lifestyle interventions are important recommendations that could improve outcomes in FH patients. However, the need to research in depth on the disproportionate impact within different subgroups should be the forefront of FH research.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Royal College of Surgeons in Ireland, Faculty of Medicine and Health Science, Dublin, Ireland.
- Aston University Medical School, Faculty of Health & Life Sciences, Aston University, Birmingham, UK.
- Epidemiology Research Unit, Cardiovascular Analytics Group, China-UK Collaboration, Hong Kong, China.
- Government Medical College and Hospital Chandigarh, Chandigarh, India.
- Barts and The London School of Medicine and Dentistry, London, UK.
- School of Biosciences, Biotechnology, University of Nottingham, Nottingham, UK.
ORCID profiles: Vikash Jaiswal, Gary Tse
Cite
APA
Huang, H., Leung, K. S. K., Garg, T., Mazzoleni, A., Miteu, G. D., Zakariya, F., Awuah, W. A., Yin, E. T. S., Haroon, F., Hussain, Z., Aji, N., Jaiswal, V., & Tse, G. (2023). Barriers and shortcomings in access to cardiovascular management and prevention for familial hypercholesterolemia during the COVID‐19 pandemic. Clinical Cardiology. https://doi.org/10.1002/clc.24059
Vancouver
Huang H, Leung KSK, Garg T, Mazzoleni A, Miteu GD, Zakariya F, et al. Barriers and shortcomings in access to cardiovascular management and prevention for familial hypercholesterolemia during the COVID‐19 pandemic. Clinical Cardiology. 2023. doi:10.1002/clc.24059
BibTeX
@article{Huang2023,
author = {Huang, Helen and Leung, Keith S K and Garg, Tulika and Mazzoleni, Adele and Miteu, Goshen D and Zakariya, Farida and Awuah, Wireko A and Yin, Elaine T S and Haroon, Faaraea and Hussain, Zarish and Aji, Narjiss and Jaiswal, Vikash and Tse, Gary},
title = {Barriers and shortcomings in access to cardiovascular management and prevention for familial hypercholesterolemia during the COVID‐19 pandemic},
journal = {Clinical Cardiology},
year = {2023},
doi = {10.1002/clc.24059}
}
EUVIMED